Group 1 - The company achieved a revenue of 1.008 billion yuan in the first half of 2025, representing a year-on-year growth of 12.51%, and a net profit attributable to shareholders of 225 million yuan [1] - The company plans to distribute a cash dividend of 1.5 yuan per 10 shares (including tax) [1] - The company owns 21 plasma collection stations, with 20 currently operational, and collected 320.39 tons of raw plasma, a year-on-year increase of 7.2% [1] Group 2 - The company’s R&D investment for the first half of the year was 44.7189 million yuan, an increase of 2.12% year-on-year [2] - The successful approval of 10% immunoglobulin for market launch marks the company as the third in China to have this product, enhancing the comprehensive utilization rate of plasma [2] - The blood products market in China is projected to reach approximately 60 billion yuan in 2024 and is expected to grow to 100 billion yuan by 2030 [2]
博雅生物上半年营收同比增长12.51%